HealthNewsAPI
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial - CNBC
Overview
Lilly’s next-generation obesity candidate retatrutide cleared a key late-stage diabetes trial, showing strong effects on blood sugar and weight and highlighting the company’s pipeline momentum. New evidence that tirzepatide also lowers cardiovascular risk raises the bar for retatrutide and other follow-on therapies to demonstrate heart-protective benefits, not just metabolic effects. Genetic links between gut-hormone genes and drug response suggest future trials and clinical use may need biomarker-driven patient selection.
Entities
ORGCNBCORGEli Lilly
Relationship Graph
Click a connection line between nodes to view confidence and evidence.
Nodes: 10 · Connections: 9
Caused by
Led to
Related to
Same event
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Click a connection for evidence · click a node to open it
Select a connection to see why these events are linked.